You are here

Targeting the Use of Acid Suppressants in Hospital Patients

Study identifies those at greatest risk for GI bleeds (Jan. 7)

Gastrointestinal (GI) bleeds that occur in the hospital, although rare, can be a significant source of morbidity and mortality. Currently, the prophylactic use of acid-suppressive medication in hospitalized, non-critically ill patients is not widely recommended. Despite this, these medications continue to be widely used for this purpose.

Researchers at Beth Israel Deaconess Medical Center in Boston, Mass., believe that there is a group of patients whose risk of GI bleeds is high enough to warrant the routine prescription of acid-suppressive medication, as well as a larger group in whom these medications can be safely withheld. The new study, which developed a risk scoring system to identify these patient groups, was published online in the Journal of General Internal Medicine.

Recent studies have found that the risk of GI bleeding in hospitalized, non-critically ill patients is fairly low. However, some patients will be at greater risk for this complication than others, and no method is currently available to help medical staff identify those most likely to experience a GI bleed. The researchers therefore set out to find factors that might identify which patients were most at risk to help target the use of prophylactic acid-suppressive medication for patients who need it, and to withhold such medication in the rest.

The researchers reviewed 75,723 admissions at their institution over a 3-year period. Patients were excluded from the analysis if they were admitted with GI bleeding, developed a bleed within 1 day of admission, or were scheduled to undergo cardiac catheterization. GI bleeds occurred in a total of 203 patients.

The researchers identified independent risk factors that increased the likelihood of a GI bleed. These factors were: age greater than 60 years; male sex; the presence of liver disease, acute renal failure, or sepsis; being on a medicine service; the use of prophylactic anticoagulants; and the presence of coagulopathy. This information enabled the investigators to develop a risk scoring system to identify high-risk groups. They found that the risk of GI bleeding increased directly in line with these clinical risk factors.

The researchers emphasize that further studies are needed to reproduce their data. However, their scoring system allows the identification of a subset of patients who may benefit from the prophylactic use of acid-suppressive therapy, as well as a larger group in whom these medications can safely be avoided.

Sources: Springer; January 7, 2013; and JGIM; January 2013.

Recent Headlines

Scenesse is new treatment for people with rare, painful light sensitivity disease
Humira, Rituxan top list of drugs that added $5.1 billion to nation's health care bill
Lower court rulings cleared the way for generic versions of the MS drug
Maryland man wins lawsuit that alleges that the company's antipsychotic caused his gynecomastia
Antidepressants, ADHD meds are also used to self-poison
Study lists steps that could save close to $300 billion a year
While many victims used THC, the cause remains elusive
Descovy joins Truvada, another Gilead product, in the HIV prophylaxis market
Data show PTC Therapeutics drug preserves lung function